IP Library Granted Patent US 8,318,930
Granted Patent B2
US 8,318,930 · App. 12/810,288 · Granted Nov 27, 2012

Process for preparing polymorphic forms of (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one

Assignee: Matrix Laboratories Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,318,930
App. No.
12/810,288
Granted
Nov 27, 2012
Kind
B2
Abstract

Disclosed herein is a novel process for preparing polymorphic Forms of (S)-6-chloro-(cyclopropylethynyl)-1,4-di-hydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one referred as M 1 , I, II, β, and ω.

Claims (19)

1. A process for preparing (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one polymorphic Form β, comprising:

dissolving efavirenz in a solvent;

cooling the reaction mass;

seeding the cooled reaction mass containing polymorphic Form β of efavirenz;

adding an anti-solvent; and

isolating the pure polymorphic Form β of (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one.

2. The process according to claim 1 , wherein the step of dissolving efavirenz in the solvent is carried out at room temperature.

3. The process according to claim 1 , wherein the solvent is selected from the group consisting of lower aliphatic alcohols, lower aliphatic carboxylic acids, hetero aromatics, polar aprotic solvents, esters, aliphatic hydrocarbons, and mixtures thereof with water.

4. The process according to claim 3 , wherein the solvent is selected from methanol, ethanol, isopropyl alcohol, formic acid, acetic acid, ethyl acetate, isopropyl acetate, dimethylformamide, 1-methyl-2-pyrrolidinone and mixtures thereof.

5. The process according to claim 1 , wherein the reaction mass is cooled to 0-10° C.

6. The process according to claim 1 , wherein the anti-solvent is selected from water, n-heptane or mixtures thereof.

7. A process for preparing (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one polymorphic Form β, comprising:

providing a mixture of water and water miscible organic solvent;

dissolving efavirenz into the mixture; and

removing the solvent and isolating the polymorphic Form β of (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one.

8. The process according to claim 7 , wherein the miscible organic solvent is selected from methanol, ethanol, isopropyl alcohol, acetone, and mixtures thereof.

9. The process according to claim 8 , wherein the solvent is removed by employing freeze drying or distillation method.

10. The process according to claim 1 , wherein the reaction mass is cooled to 0-5° C.

11. The process according to claim 1 , wherein the anti-solvent comprises water.

Assignments (4)
CHANGE OF NAME Recorded Jan 12, 2026
From: TIANISH LABORATORIES PRIVATE LIMITED
To: MATRIX PHARMACORP PRIVATE LIMITED
Reel/Frame 074322/0525 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: MYLAN LABORATORIES LIMITED
To: TIANISH LABORATORIES PRIVATE LIMITED
Reel/Frame 068861/0150 →
CHANGE OF NAME Recorded Jul 29, 2013
From: MATRIX LABORATORIES LIMITED
To: MYLAN LABORATORIES LIMITED
Reel/Frame 030898/0514 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2010
From: TYAGI, OM DUTT; JETTI, RAM K. R.; RAMIREDDY, B. A.
To: MATRIX LABORATORIES LIMITED
Reel/Frame 024962/0955 →
Priority Claims (1)
IN 3080/CHE/2007 · Dec 24, 2007 · national
Continuity (1)
Related Publication 20100274007A1 · Oct 28, 2010